Sign in
CompletedNo phase

Comparison of Phoenixin-14 Levels in Term Babies

Key facts

Who runs it
Konya City Hospital
Where
Türkiye1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
160 people enrolled
Started
1 Dec 2022
Ended
30 Apr 2024
Type of study
Observational, 4 groups
Record updated
24 October 2024

Who can take part

Age
1 Minute to 1 Minute
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 6 criteriaShow less

Who can take part

  • Healthy term infants (born between 37+0 and 42+6 weeks) delivered by spontaneous vaginal delivery or cesarean section were included in the study

Who cannot take part

  • Infants with multiple congenital anomalies
  • Chorioamnionitis
  • Preeclampsia
  • Mothers had premature rupture of membranes,
  • Requiring intensive care unit

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

INTRODUCTION Birth weight and pregnancy week are determinants of mortality and morbidity of newborn infants. Birth weights by gestational week are associated with accompanying diseases in the later stages of life (1). Infants with a birth weight below the 10th percentile by gestational week are defined as small for gestational age (SGA), those with a birth weight above the 90th percentile are defined as large for gestational age (LGA), and those with a birth weight between the 10th and 90th percentiles are defined as appropriate for gestational age (AGA) (2). In LGA and SGA infants, problems such as hypoglycemia, hypoxia, polycythemia, and respiratory support may be encountered in the neonatal period. These infants may also experience diseases that affect the quality and duration of life at later ages, such as metabolic syndrome, obesity, cardiovascular diseases, and diabetes mellitus (1, 2). Gestational diabetes mellitus (GDM) is the most common complication during pregnancy and is defined as any degree of glucose intolerance that begins or is first recognized during pregnancy (3). GDM has long been associated with obstetric and neonatal complications, particularly those related to high birth weight, and is increasingly recognized as a risk factor for future cardiometabolic disease in the child. As the causes of serious health problems can be attributed to maternal illness or changes in birth weight, these issues continue to be investigated (4).

Read full original descriptionShow less

Phoenixin (PNX) is a neuropeptide first described by Yosten et al. in 2013 (5). The most common isoforms of PNX, phoenixin-14 (PNX-14) and phoenixin-20 (PNX-20), exhibit similar biological activities and are peptides composed of 14 and 20 amino acids, respectively (5). In the initial characterization of PNX, it was reported to be crucial for normal reproductive function through its effects on the hypothalamus-pituitary-gonadal axis. The literature provides further evidence for the role of PNX in reproductive functions and suggests that it also plays a role in other aspects of brain-mediated and peripheral physiology. In addition, there is some evidence demonstrating that PNX affects the heart, diet, memory, and anxiety (6). Animal studies of PNX-14 have shown that PNX-14 has an important role in the central control of feeding behavior and metabolic homeostasis. In addition to correlations between PNX-14 and body mass index (BMI), studies have shown that PNX-14 modulates food intake and feeding behavior (7). PNX-14 is a neuropeptide known to prevent oxidative damage and stimulate insulin secretion. Animal studies have shown that PNX-14 treatments prevent pancreatic damage and β-cell loss by reducing oxidative stress (8). A study indicating that PNX-14 plays an important role in the occurrence of diabetes and obesity found that PNX-14 concentrations were significantly lower in patients with type 2 diabetes mellitus than in healthy individuals (9, 10).

In this study, we investigated the relationships between normal (AGA), low (SGA), and high (LGA) birth weight according to gestational week of pregnancy and phoenixin-14 levels in the umbilical cord blood of healthy infants of healthy mothers and infants of mothers diagnosed with GDM regardless of birth weight.

The 4 groups in the trial

  • 1. Small for Gestational Age Babies (SGA)

    Infants with birth weight below the 10th percentile are classified as small for gestational age (SGA

  • 2. Large for Gestational Age Babies (LGA)

    infants above the 90th percentile are classified as large for gestational age (LGA)

  • 3. Appropriate for Gestational Age Babies (AGA)

    between the 10th and 90th percentiles are classified as appropriate for gestational age

  • 4. GDM

    babies of Mothers with gestational diabetes mellitus

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
COMPARISON OF PHOENIXIN-14 LEVELS IN UMBILICAL CORD BLOOD ACCORDING TO BIRTH WEIGHT IN TERM INFANTS: ARE PHOENIXIN-14 LEVELS LINKED TO BIRTH WEIGHT AND MATERNAL DIABETES?
Record updated
24 October 2024